Nymox Pharm Corp (NYMX) 3.35 $NYMX Nymox (NYMX) Stock Up

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Nymox Pharm Corp (NYMX) 3.35 $NYMX

Nymox (NYMX) Stock Up on Positive 7-Year Fexapotide Data
Zacks Equity Research - Zacks Investment Research - Thu Jun 23, 7:51AM CDT
Nymox (NYMX) announced positive results from the seven-year, prospective, placebo-controlled, double-blind study on fexapotide (NX-1207).
ANIP: 61.06 (+0.46), PFE: 37.31 (+0.42), RTRX: 18.17 (+0.24), NYMX: 3.35 (-0.25)

Nymox reports 1Q loss
Automated Insights - Mon May 16, 5:11PM CDT
MONTREAL (AP) _ Nymox Pharmaceutical Corp. (NYMX) on Monday reported a first-quarter loss of $3.3 million, after reporting a profit in the same period a year earlier.
NYMX: 3.35 (-0.25)

Nymox Announces Prostate Cancer Clinical Trial Results From Completed 18 Month Endpoint Study
GlobeNewswire - Tue Feb 09, 10:07AM CST
Nymox Pharmaceutical Corporation (NASDAQ:NYMX) today announced results from the completion of the Company's U.S. 40 month (18 month outcomes) localized prostate cancer Phase 2 NX03-0040 clinical trial of fexapotide triflutate (NX-1207). The study successfully met its pre-determined endpoints. Cancer progression clinical outcomes were significantly improved in the fexapotide treated patient groups.
NYMX: 3.35 (-0.25)

Nymox raises another USD2.1m from equity financing
M2 - Fri Feb 05, 5:02AM CST
Biopharmaceutical company Nymox Pharmaceutical (NasdaqCM:NYMX) reported on Thursday the completion of USD2.1m private placement equity investment at USD2.00 per share with no warrants.
NYMX: 3.35 (-0.25)

Escherichia Coli Infections - Pipeline Review, H2 2015
M2 - Mon Feb 01, 10:20AM CST
Research and Markets (http://www.researchandmarkets.com/research/96468r/escherichia_coli) has announced the addition of the "Escherichia coli Infections - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Escherichia Coli Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Escherichia Coli Infections and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Escherichia Coli Infections Overview - Therapeutics Development - Pipeline Products for Escherichia Coli Infections - Overview - Pipeline Products for Escherichia Coli Infections - Comparative Analysis - Escherichia Coli Infections - Therapeutics under Development by Companies - Escherichia Coli Infections - Therapeutics under Investigation by Universities/Institutes - Escherichia Coli Infections - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Escherichia Coli Infections - Products under Development by Companies - Escherichia Coli Infections - Products under Investigation by Universities/Institutes - Escherichia Coli Infections - Companies Involved in Therapeutics Development - Adenium Biotech ApS - Arsanis Biosciences GmbH - AstraZeneca Plc - AvidBiotics Corp. - Bioorganic Research and Services S.A. - Cellceutix Corporation - Chiesi Farmaceutici SpA - Debiopharm International S.A. - Emergent BioSolutions Inc. - F. Hoffmann-La Roche Ltd. - GangaGen Inc. - GlaxoSmithKline Plc - Immuron Limited - Melinta Therapeutics, Inc - Microbiotix, Inc. - MicuRx Pharmaceuticals, Inc. - Mucosis B.V. - Navigen Pharmaceuticals, Inc. - Nosopharm SAS - Novabiotics Limited - Nymox Pharmaceutical Corporation - Pherecydes Pharma SA - Phico Therapeutics Limited - Procarta Biosystems Ltd - Sanofi Pasteur SA - Sealife PHARMA GMBH - Sequoia Sciences, Inc. - Soligenix, Inc. - Syntiron LLC - Tetraphase Pharmaceuticals Inc. - Trana Discovery, Inc. - Varinel, Inc. For more information visit http://www.researchandmarkets.com/research/96...ichia_coli
TTPH: 4.19 (+0.17), EBS: 30.97 (-2.42), AZN: 33.84 (-0.30), NYMX: 3.35 (-0.25), GSK: 45.25 (+0.18)

Nymox Files Current Financial Statements
GlobeNewswire - Thu Dec 31, 3:45PM CST
Nymox Pharmaceutical Corporation (NASDAQ:NYMX) is pleased to announce that today the Company has filed its third quarter 2015 and restated second quarter 2015 financial statements. The financial results are available at - http://www.sec.gov/cgi-bin/browse-edgar?compa...getcompany. The restatement of Q2 2015 was required in order to correct a material accounting error in stock option compensation expense.
NYMX: 3.35 (-0.25)

Nymox Provides Update From Shareholders Annual General Meeting December 16
GlobeNewswire - Thu Dec 17, 8:00AM CST
Nymox Pharmaceutical Corporation (NASDAQ:NYMX) is pleased to report an update on the Corporation's business as of December 16, 2015. At the Company's AGM in Nassau, the following highlights were presented:
NYMX: 3.35 (-0.25)

World Benign Prostatic Hyperplasia Therapeutics Pipeline Review 2015 - 25 Companies & 36 Drug Profiles
M2 - Mon Dec 14, 8:38AM CST
Research and Markets (http://www.researchandmarkets.com/research/46clxb/benign_prostatic) has announced the addition of the "Benign Prostatic Hyperplasia - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Benign Prostatic Hyperplasia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Benign Prostatic Hyperplasia and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Addex Therapeutics Ltd - AmVac AG - AndroScience Corporation - Aphios Corporation - Ausio Pharmaceuticals, LLC - BCWorld Pharm Co. Ltd. - Biolab Sanus Farmaceutica Ltda. - Chong Kun Dang Pharmaceutical Corp. - Dongkook Pharmaceutical Co., Ltd. - Euroscreen S.A. - Hanmi Pharmaceuticals, Co. Ltd. - IntelGenx Corp. - Jeil Pharmaceutical Co., Ltd. - KAEL-GemVax Co., Ltd. - Kaken Pharmaceutical Co., Ltd. - Meiji Seika Pharma Co., Ltd. - Mezzion Pharma Co. Ltd. - Monosol Rx, LLC - Nymox Pharmaceutical Corporation - Ono Pharmaceutical Co., Ltd. - Quest PharmaTech Inc. - SK Chemicals Co., Ltd. - SOM Innovation Biotech SL - Sophiris Bio, Inc. - Yungjin Pharm. Co., Ltd. Drug Profiles - (dutasteride tadalafil) - (solifenacin succinate tamsulosin hydrochloride) - (tamsulosin hydrochloride dutasteride) - ADX-68692 - AMV-110 - ASC-JM.X2 - AUS-131 - BCWPE-004 - BL-214 - CKD-902 - ESN-364 - fexapotide triflutate - HCP-1303 - HIP-1402 - INT-0031 - L-1AD3 - MCS-2 - Micselon - NCE-403 - ONO-8430506 - S-40542 - SL-052 - Small Molecules to Inhibit Steroidal 5-Alpha Reductase for Benign Prostatic Hyperplasia - SOM-2391 - SOM-2393 - Sperol - Synthetic Peptide to Antagonize GPR54 for Womens Health, Male Health and Oncology - tadalafil - talaporfin sodium - tamsulosin hydrochloride CR - tamsulosin hydrochloride DR - tertomotide - topsalysin - udenafil - YBH-1603 For more information visit http://www.researchandmarkets.com/research/46..._prostatic
SPHS: 5.49 (-0.37), NYMX: 3.35 (-0.25)

Analyst Insights behind Price Movement - Research on Vascular Biogenics, Hutchinson Technology, Tonix Pharmaceuticals and Nymox Pharmaceutical
ACCESSWIRE - Mon Nov 23, 7:40AM CST
NEW YORK, NY / ACCESSWIRE / November 23, 2015 / Moments ago, Trader's Choice released new research updates concerning several important developing situations including the following equities: Vascular Biogenics Ltd (NASDAQ: VBLT), Hutchinson Technology Inc (NASDAQ: HTCH), Tonix Pharmaceuticals Holding Corp (NASDAQ: TNXP) and Nymox Pharmaceutical Corp (NASDAQ: NYMX). Trader's Choice has perfected the profitable art of picking stocks, cutting through the noise to deliver the top trade, every year. The full Research Packages are being made available to the public on a complimentary basis.
HTCH: 1.67 (-0.30), TNXP: 2.05 (-0.02), NYMX: 3.35 (-0.25), VBLT: 3.97 (-0.05)

Urinary Tract Infections - Pipeline Review, H2 2015
M2 - Fri Nov 06, 9:54AM CST
Research and Markets (http://www.researchandmarkets.com/research/fx43r6/urinary_tract) has announced the addition of the "Urinary Tract Infections - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Urinary Tract Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Urinary Tract Infections and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Mentioned - Achaogen Inc. - Adenium Biotech ApS - AstraZeneca Plc - ConjuGon, Inc. - Da Volterra - DexTech Medical AB - Enteris BioPharma, Inc. - GlaxoSmithKline Plc - Melinta Therapeutics, Inc - Merck & Co., Inc. - MerLion Pharmaceuticals Pte Ltd - Nabriva Therapeutics AG - Nippon Shinyaku Co., Ltd. - NovaBay Pharmaceuticals, Inc. - Nymox Pharmaceutical Corporation - Paratek Pharmaceuticals, Inc. - Pivot Pharmaceuticals Inc - Sequoia Sciences, Inc. - Shionogi & Co., Ltd. - Syntiron LLC - The Medicines Company - Zensun (Shanghai) Sci & Tech Co., Ltd. For more information visit http://www.researchandmarkets.com/research/fx...nary_tract
MRK: 58.66 (unch), AZN: 33.84 (-0.30), AKAO: 3.65 (-0.28), NYMX: 3.35 (-0.25), PRTK: 13.02 (+0.15), GSK: 45.25 (+0.18), NBRV: 8.33 (-0.10)

Nymox Reports Results of Prospective Cross-Over Study of Fexapotide Treatment for Prostate Cancer
GlobeNewswire - Thu Oct 29, 9:31AM CDT
Nymox Pharmaceutical Corporation (NASDAQ:NYMX) reported today that long-term randomized cross-over data from the Company's trial of fexapotide triflutate for low grade localized prostate cancer has shown statistical significance in efficacy compared to controls. The study results indicate that randomized control subjects who subsequently switched to fexapotide had long-term outcomes significantly superior to control patients who did not change (cross-over) to fexapotide treatment.
NYMX: 3.35 (-0.25)

Nymox Announces Prostate Cancer Clinical Trial Will Complete Prospective 18 Month Post-Treatment Assessments
GlobeNewswire - Thu Oct 08, 10:00AM CDT
Nymox Pharmaceutical Corporation (NASDAQ:NYMX) announced today that that participants in prostate cancer clinical trial NX03-0040 had neared completion of the study's 18 month post-treatment assessments. The results from this 18 month study are expected to be reported this quarter, after the 18 month data has been analyzed. Patients in the prostate cancer study have been followed for up to 39 months after treatment.
NYMX: 3.35 (-0.25)

Technical Coverage On Stocks From Diverse Sectors -- Bill Barrett, Nymox Pharmaceutical, GoPro, Mondelez International, and Tesla Motors
PR Newswire - Tue Sep 22, 7:12AM CDT
ACI Association has initiated research coverage on the following equities: Bill Barrett Corp (NYSE: BBG), Nymox Pharmaceutical Corporation (NASDAQ: NYMX), GoPro Inc (NASDAQ: GPRO), Mondelez International Inc (NASDAQ: MDLZ), and Tesla Motors Inc (NASDAQ: TSLA). On Monday, September 21, 2015, Nasdaq ended at 4,828.95 up 0.04%, DOW advanced 0.77%, to finish the day at 16,510.19, and the S&P closed at 1,966.97, up 0.46%. Register for your complimentary reports at the links given below.
TSLA: 230.01 (-4.78), GPRO: 12.94 (+0.30), MDLZ: 43.48 (-0.50), BBG: 5.50 (-0.47), NYMX: 3.35 (-0.25)

Nymox Announces Change of Company's Domicile and Head Office
GlobeNewswire - Tue Aug 04, 10:45AM CDT
Nymox Pharmaceutical Corporation (NASDAQ:NYMX) is pleased to announce that the Company has received formal approvals for its change of domicile to the Bahamas effective July 31, 2015.
NYMX: 3.35 (-0.25)

Escherichia Coli Infections - Pipeline Review, H1 2015: Analysis of 35 Companies & 62 Drug Profiles
M2 - Fri Jul 31, 8:36AM CDT
Research and Markets (http://www.researchandmarkets.com/research/9xjrsw/escherichia_coli) has announced the addition of the "Escherichia Coli Infections - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Escherichia Coli Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Escherichia Coli Infections and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Adenium Biotech ApS - Arsanis Biosciences GmbH - AvidBiotics Corp. - Bellus Health Inc. - Bioorganic Research and Services S.A. - Cellceutix Corporation - Chiesi Farmaceutici SpA - ConjuGon, Inc. - Debiopharm International S.A. - Emergent BioSolutions Inc. - F. Hoffmann-La Roche Ltd. - GangaGen Inc. - Genentech, Inc. - GlaxoSmithKline Plc - Immuron Limited - Melinta Therapeutics, Inc - Microbiotix, Inc. - Mucosis B.V. - Nabriva Therapeutics AG - Navigen Pharmaceuticals, Inc. - Northern Antibiotics Oy - Nosopharm SAS - NovaBay Pharmaceuticals, Inc. - Novabiotics Limited - Nymox Pharmaceutical Corporation - Pherecydes Pharma SA - Phico Therapeutics Limited - Procarta Biosystems Ltd - Sanofi Pasteur SA - Sealife PHARMA GMBH - Sequoia Sciences, Inc. - Soligenix, Inc. - Spider Biotech - Syntiron LLC - Trana Discovery, Inc. For more information visit http://www.researchandmarkets.com/research/9x...ichia_coli
EBS: 30.97 (-2.42), NYMX: 3.35 (-0.25), GSK: 45.25 (+0.18), NBRV: 8.33 (-0.10)

Nymox elects James G. Robinson to board
M2 - Fri Jul 31, 4:25AM CDT
Biopharmaceutical company Nymox Pharmaceutical (NasdaqCM:NYMX) revealed on Thursday that it has appointed James G. Robinson to its board of directors.
NYMX: 3.35 (-0.25)

Nymox Announces Appointment of James G. Robinson to Board of Directors
GlobeNewswire - Thu Jul 30, 10:15AM CDT
Nymox Pharmaceutical Corporation (NASDAQ:NYMX) is pleased to announce that the Company has newly appointed James G. Robinson to the Board of Directors.
NYMX: 3.35 (-0.25)

Nymox July 27 Webcast of New BPH Clinical Trial Results Posted Today Online
GlobeNewswire - Tue Jul 28, 11:00AM CDT
Nymox's (NASDAQ:NYMX) July 27 webcast of news and discussion by experts of the Company's new clinical trial results can be viewed at http://limelightdc.com/clientarea/nymox_inves...r_vod.html. The link is also available at the Company's website.
NYMX: 3.35 (-0.25)

Nymox Pivotal Phase 3 NX-1207 BPH Extension Trial Successfully Meets Primary Endpoint. Company Plans to File for Regulatory Approvals for Fexapotide Triflutate (NX-1207).
GlobeNewswire - Mon Jul 27, 8:30AM CDT
Nymox Pharmaceutical Corporation (NASDAQ:NYMX) announced today that the Company's U.S. long-term extension prospective double-blind Phase 3 BPH studies NX02-0017 and NX02-0018 of fexapotide triflutate (NX-1207) for BPH have successfully met the pre-specified primary endpoint of long-term symptomatic statistically significant benefit superior to placebo. Fexapotide showed an excellent safety profile with no evidence of drug-related short-term or long-term toxicity nor any significant related molecular side effects in the 2 studies (n=978).
NYMX: 3.35 (-0.25)

Nymox Appoints Cutler & Co. as Auditor
GlobeNewswire - Thu Jul 16, 5:03PM CDT
On July 15, 2015, the Board of Directors of Nymox Pharmaceutical Corporation (NASDAQ:NYMX) approved the engagement of Cutler & Co., LLC to serve as the Company's new independent registered public accounting firm to replace KPMG LLP. Prior to the date of Cutler's engagement, the Company has not consulted with Cutler regarding (i) the application of accounting principles to a specific completed or contemplated transaction, (ii) the type of audit opinion that might be rendered on the Company's financial statements and neither a written report was provided to the registrant nor oral advice was provided that the new accountant concluded was an important factor considered by the registrant in reaching a decision as to the accounting, auditing or financial reporting issue; or (iii) any matter that was either the subject of a disagreement.
NYMX: 3.35 (-0.25)

Scroll down for more posts ▼

Top 10 Most Recent News Articles

DEFSEC Tackles Nasdaq Bid Price Hurdle with Share Move

Updated Category News Views 68

Navigating Bid Price Deficiency Issues Well, it seems DEFSEC Technologies Inc. found themselves in a tricky spot last week. A nasty gram from Nasdaq’s Listing Qualifications Department pointing out that DEFSEC's shares had dipped below that $1.00 per share requirement for too long—a full 30 business days. Now, don't panic just yet. This isn't about the shares getting...

Continue Reading
Broadridge Brings Boyman In to Sharpen Its Market Story

Updated Category News Views 66

Financial plumbing rarely gets applause, which is precisely why Broadridge needs somebody who can explain its value without turning the pitch into alphabet soup. Lauren Boyman arrives as chief marketing and communications officer on November 23, taking charge of global marketing, corporate communications, product positioning, digital strategy, lead generation and thought...

Continue Reading
Frontline Claims Survey Tests AI's Real Desk Impact

Updated Category News Views 45

Claims software can look brilliant in a conference-room demo and still create a fresh pile of headaches for the person handling a real injured worker’s file. That is why the 2026 Workers’ Compensation Benchmarking Study opening its survey to frontline claims professionals matters more than the usual industry questionnaire. This is an operating-reality check, not just...

Continue Reading
1095 Days Finds the Army's Long, Ordinary War Life

Updated Category News Views 14

A cracked barracks window can explain more than a polished battlefield legend. Dean R. Cherry's 1095 Days: Three Years in the Green Machine, newly released by Palmetto Publishing, puts its weight on the parts of Army life that war stories often shove into the background: cold, waiting, paperwork, arbitrary rules, lousy living conditions, and the private mental math of...

Continue Reading
Trucking Hub Bets on Faster MVR Checks Nationwide Today

Updated Category News Views 38

Driver paperwork is where plenty of supposedly modern fleet systems still go to die. Trucking Hub’s Nov. 18 launch of GetMVR.com takes a clean swing at that mess: an online platform for ordering Motor Vehicle Records in all 50 states, with instant reports available in 48. It is not glamorous software, and frankly that is why it may matter. Fleets do not lose sleep over...

Continue Reading
LAFC Turns Empty Seats Into an AI Test Case for Sports

Updated Category News Views 180

Empty seats are a lousy kind of inventory A vacant stadium seat is perishable inventory with the clock screaming at it. LAFC and AccelerAI have aimed their first co-developed AI project at that unglamorous but important problem: getting more ticket holders through the gate without simply hacking prices down at the last minute. That is a far more sensible use of artificial...

Continue Reading
Navan’s Travel Survey Sells Friction as a Business Case

Updated Category News Views 167

A forgotten charger can turn a routine trip into a small mutiny. That is the useful little truth sitting underneath Navan’s new survey of 2,000 Americans who travel for leisure or business. The company is poking at the annoyances people carry from the bedroom packing pile to the jet bridge: forgotten items, rushed airport arrivals, pre-flight drinks, chatty strangers,...

Continue Reading
Health In Tech Brings a Tech Veteran Onto Its Board

Updated Category News Views 31

Board appointments rarely make the cash register ring, but they can tell you where management thinks the next bruises are coming from. Health In Tech has added Tim Cortes as an independent director, put him in charge of the Compensation Committee, and placed him on both the Audit and Nominating and Corporate Governance Committees. For an AI-enabled insurance technology...

Continue Reading
De Beers Puts Namibia's 176-Carat Owishi on Display

Updated Category News Views 54

A 176-carat natural diamond can still make a room stop breathing, even in a trade battered by arguments over lab-grown supply, luxury spending, and what “rare” ought to mean anymore. De Beers Group, working with Grandview Klein Diamond, has unveiled Namibia’s Owishi natural diamond in Washington, DC. That is the hard fact on the table: a large Namibian stone, a U.S....

Continue Reading
Katahdin's Portland Branch Bet Moves Downtown in 2027

Updated Category News Views 0

Exchange Street is getting a real-world vote of confidence, and that is more interesting than another app update ever will be. Katahdin Trust intends to open a full-service branch at 120 Exchange Street in downtown Portland, with renovations slated to begin early in 2027 and an opening expected later that year. For a Maine community bank with nearly $1.2 billion in...

Continue Reading

Top 5 Most Recently Viewed Articles

Prinses Máxima Center Enhances Genomics with Callisto™ Innovation

Updated Category News Views 300

Prinses Máxima Center's Partnership with Volta Labs The Prinses Máxima Center for Pediatric Oncology is making headlines with its recent acquisition of the Callisto™ platform from Volta Labs. This major step forward aims to enhance efficiency in sample preparation across a variety of genomics workflows, specifically designed for both Illumina and Oxford Nanopore...

Continue Reading
Keros Therapeutics to Showcase Innovations at Key Conferences

Updated Category News Views 152

Exciting Participation of Keros Therapeutics in Major Conferences Keros Therapeutics, Inc. is making significant strides in the biopharmaceutical landscape by focusing on innovative therapies targeting disorders associated with the TGF-ß family of proteins. Recently, the company announced that its Chair and Chief Executive Officer, Jasbir S. Seehra, Ph.D., will represent...

Continue Reading
KULR Technology Unveils Major Licensing Breakthrough with Japan

Updated Category News Views 133

KULR Technology Group, Inc. (NYSE American: KULR) unveiled a major licensing agreement back in 2024 that had traders buzzing. This $2.35 million deal centered around their vibration reduction technology, known as KULR Xero Vibe (KXV). At first glance, it seemed like a solid step for the company into new markets, but let’s peel back the layers and see what's really...

Continue Reading
Mainz Biomed Achieves Significant Milestones and Results

Updated Category News Views 204

Mainz Biomed Reports Financial Results and Strategic Progress Lab network revenue up by 33% year-over-year. Operating loss down by 30% and net loss by 18%. Partnerships driving innovation and growth forward. Highlighting 2025 accomplishments and future goals. Mainz Biomed N.V. (NASDAQ: MYNZ), a pioneering molecular genetics diagnostic firm, has reported its financial...

Continue Reading
PioCreat Launches Innovative Mini Dental 3D Printer During Expo

Updated Category News Views 247

PioCreat Launches Innovative Mini Dental 3D Printer at Moscow Event PioCreat, a well-respected name in the 3D printing sector, made a significant impression at the dental industry's notable event, the 2025 Moscow Dental Expo. This gathering, renowned for showcasing advancements in digital dentistry, took place at Crocus-Expo IEC, attracting a wide array of international...

Continue Reading